^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SNC109

    i
    Other names: SNC109, SNC 109, SNC-109
    Associations

    News

    Trials
    Company:
    Shanghai Simnova Bio
    Drug class:
    HER2-targeted CAR-T immunotherapy, EGFR-targeted CAR-T immunotherapy, EGFRvIII-targeted CAR-T immunotherapy, IL-13Rα2-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    3ms
    The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM (clinicaltrials.gov)
    P1, N=50, Enrolling by invitation, Shanghai Simnova Biotechnology Co.,Ltd.
    New P1 trial • CAR T-Cell Therapy
    |
    SNC109
    10ms
    The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=16, Recruiting, Shanghai Simnova Biotechnology Co.,Ltd. | Trial primary completion date: Aug 2023 --> May 2024
    Trial primary completion date • CAR T-Cell Therapy
    |
    SNC109
    over1year
    The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=16, Recruiting, Shanghai Simnova Biotechnology Co.,Ltd.
    New P1 trial • CAR T-Cell Therapy
    |
    IL6 (Interleukin 6)
    |
    SNC109